AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Slideshow
…
13,189$
0,84%
Echtzeit-Aktienkurs Angiodynamics Inc.
Bid:
Ask:
Nachrichten zur Angiodynamics Inc. Aktie
AngioDynamics (ANGO) Upgraded to Buy: Heres Why
AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a…
ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down
AngioDynamics tops estimates as revenue rises and losses narrow, driven by Med Tech demand, even as gross margin slips.…
Quant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lag
…
Does AngioDynamics (ANGO) Have the Potential to Rally 92.15% as Wall Street Analysts Expect?
The mean of analysts price targets for AngioDynamics (ANGO) points to a 92.2% upside in the stock. While this highly…
Down 25.0% in 4 Weeks, Heres Why You Should You Buy the Dip in AngioDynamics (ANGO)
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This,…
ANGO Stock Dips Despite Q2 Earnings Beat, Gross Margin Improves
AngioDynamics reports flat Q2 earnings while revenue increase 8.8% and gross margin expands 170 bps on stronger Med Tech performance.…
AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript
…
Angiodynamics (ANGO) CEO Clemmer buys $111,500 in shares By Investing.com
Angiodynamics (ANGO) CEO Clemmer buys $111,500 in shares…
Why Did AngioDynamics Stock Pop Today?
Even 37 years after its founding, AngioDynamics still cant earn a profit.…
AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript
…
Earnings call transcript: AngioDynamics beats Q1 FY2026 forecasts, shares surge By Investing.com
Earnings call transcript: AngioDynamics beats Q1 FY2026 forecasts, shares surge…
AngioDynamics: MedTech-Wachstum von 26 % - Spezialist für Krebs- und Gefäßerkrankungen mit neuem Kaufsignal!
AngioDynamics (ANGO) konzentriert sich als Medizintechnikunternehmen auf minimalinvasive Behandlungslösungen von Krebs und peripheren Gefäßerkrankungen. Das wachstumsstarke MedTech-Segment erhöht das... …
AngioDynamics earnings beat by $0.02, revenue topped estimates By Investing.com
AngioDynamics earnings beat by $0.02, revenue topped estimates…
ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines
AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss…
Why AngioDynamics Stock Popped, Then Dropped Today
AngioDynamics big Q4 earnings beat wasnt as impressive as it first seemed.…
AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript
…
What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Lets find out.…
AngioDynamics (ANGO) Down 6.4% Since Last Earnings Report: Can It Rebound?
AngioDynamics (ANGO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?
Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.…
AngioDynamics dürfte im freundlichen Marktumfeld rasch am Allzeithoch notieren
AngioDynamics (ANGO) durchläuft einen Transformationsprozess und will sich auf wachstumsstarke Medizintechnikmärkte wie Prostatakrebs oder Thrombektomie konzentrieren. Das adressierbare Marktpotenzial... …
AngioDynamics im Pivotal-Point-Check: 22 % Umsatzwachstum in Q3 - NanoKnife und Thrombektomie treiben MedTech-Segment an!
Strategischer Fokus auf die Erweiterung des MedTech-Angebots führt zu einem beeindruckenden Umsatzwachstum von 22,2 % in diesem Segment. Kreditlinie…
AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript
…
AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of 123.08% and 2%, respectively, for the quarter ended February 2025. Do the…
AngioDynamics (ANGO) Down 14.2% Since Last Earnings Report: Can It Rebound?
AngioDynamics (ANGO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…
AngioDynamics startet nach Quartalszahlen und FDA-Zulassung für NanoKnife durch - Canaccord stuft auf 15 USD (Buy)!
AngioDynamics (ANGO) befindet sich laut CEO Jim Clemmer in diesem Jahr an einem wichtigen Wendepunkt für die Unternehmensentwicklung. In…
AngioDynamics: A Surgical Approach To Market Growth
…
AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript
…
AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of 63.64% and 2.36%, respectively, for the quarter ended November 2024. Do the…
Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?
AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend…
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
AngioDynamics latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient…
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Heres is How to Trade
The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after…
[Latest] Global Embolic Protection Device Market Size/Share Worth USD 3,562.2 Million by 2033 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
AngioDynamics announces the receipt of CPT Category I code for IRE technology.…
AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med…
AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript
…
AngioDynamics, Inc. 2025 Q1 - Results - Earnings Call Presentation
…
ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe
AngioDynamics RECOVER-AV trial evaluates the AlphaVac F1885 Systems safety and efficacy in treating acute pulmonary embolism in Europe.…
Does AngioDynamics (ANGO) Have the Potential to Rally 77.03% as Wall Street Analysts Expect?
The mean of analysts price targets for AngioDynamics (ANGO) points to a 77% upside in the stock. While this highly…
AngioDynamics: Lumpy Progress Is Still Progress
…
AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down
AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the…
Earnings call: AngioDynamics sees steady growth in FY 2024 results By Investing.com
Earnings call: AngioDynamics sees steady growth in FY 2024 results…
AngioDynamics (ANGO) Q4 2024 Earnings Call Transcript
…
AngioDynamics (ANGO) AlphaVac System Gets CE Mark Approval
AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range…
AngioDynamics: A Story To Monitor
…
Earnings call: AngioDynamics posts mixed Q3 results, focuses on growth By Investing.com
Earnings call: AngioDynamics posts mixed Q3 results, focuses on growth…
AngioDynamics (ANGO) AlphaVac Gets FDA Nod for PE Treatment
AngioDynamics (ANGO) announces the FDAs approval of its AlphaVac F1885 System, which is likely to expand the range of therapy…
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.…
AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript
…
AngioDynamics (ANGO) Settles Patent Litigations With BD
AngioDynamics (ANGO) announces its settlement agreement with BDs affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.…